Aurélien Archier1,2,3, Arthur Varoquaux4, Philippe Garrigue1,5, Marion Montava6, Carole Guerin7, Sophie Gabriel1,2, Eva Beschmout4, Isabelle Morange8, Nicolas Fakhry6, Frédéric Castinetti8, Frédéric Sebag7, Anne Barlier9, Anderson Loundou10, Benjamin Guillet1,5, Karel Pacak11, David Taïeb12,13,14. 1. Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France. 2. European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France. 3. Institut Paoli-Calmettes, Inserm UMR1068 Marseille Cancerology Research Center, Marseille, France. 4. Department of Medical Imaging, Conception Hospital, Aix-Marseille University, Marseille, France. 5. Department of Radiopharmacy, La Timone & North University Hospital, Aix-Marseille University, Marseille, France. 6. Department of Otorhinolaryngology-Head and Neck Surgery, Conception Hospital, Aix-Marseille University, Marseille, France. 7. Department of Endocrine Surgery, Conception Hospital, Aix-Marseille University, Marseille, France. 8. Department of Endocrinology, Conception Hospital, Aix-Marseille University, Marseille, France. 9. Laboratory of Biochemistry and Molecular Biology, Conception Hospital, Aix-Marseille, University, Marseille, France. 10. Department of Public Health, Aix-Marseille University, Marseille, France. 11. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, MD, 20892, USA. 12. Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France. david.taieb@ap-hm.fr. 13. European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France. david.taieb@ap-hm.fr. 14. Institut Paoli-Calmettes, Inserm UMR1068 Marseille Cancerology Research Center, Marseille, France. david.taieb@ap-hm.fr.
Abstract
PURPOSE: Pheochromocytomas/paragangliomas (PHEOs/PGLs) overexpress somatostatin receptors and recent studies have already shown excellent results in the localization of these tumors using (68)Ga-labeled somatostatin analogs ((68)Ga-DOTA-SSA), especially in patients with germline succinate dehydrogenase subunit B gene (SDHB) mutations and head and neck PGLs (HNPGLs). The value of (68)Ga-DOTA-SSA has to be established in sporadic cases, including PHEOs. Thus, the aim of this study was to compare (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging in patients with various PHEOs/PGLs with a special emphasis on sporadic cases, including those located in the adrenal gland. DESIGN: (68)Ga-DOTATATE, (18)F-FDOPA PET/CT, and conventional imaging (contrast-enhanced CT and MRI with MR angiography sequences) were prospectively performed in 30 patients (8 with SDHD mutations, 1 with a MAX mutation and 21 sporadic cases) with PHEO/PGL at initial diagnosis or relapse. RESULTS: The patient-based sensitivities were 93 % (28/30), 97 % (29/30), and 93 % (28/30) for (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging, respectively. The lesion-based sensitivities were 93 % (43/46), 89 % (41/46), and 76 % (35/46) for (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging respectively (p = 0.042). (68)Ga-DOTATATE PET/CT detected a higher number of HNPGLs (30/30) than (18)F-FDOPA PET/CT (26/30; p = 0.112) and conventional imaging (24/30; p = 0.024). (68)Ga-DOTATATE PET/CT missed two PHEOs of a few millimeters in size and a large recurrent PHEO. One lesion was considered false-positive on (68)Ga-DOTATATE PET/CT and corresponded to a typical focal lesion of fibrous dysplasia on MRI. Among the 11 lesions missed by conventional imaging, 7 were detected by conventional imaging with knowledge of the PET results (4 HNPGLs, 2 LNs, and 1 recurrent PHEO). CONCLUSION: (68)Ga-DOTATATE PET/CT is the most sensitive tool in the detection of HNPGLs, especially SDHD-related tumors, which may be very small and fail to concentrate sufficient (18)F-FDOPA. The present study further expands the use of (68)Ga-DOTATATE for all patients with HNPGLs, regardless of their genotype. (68)Ga-DOTATATE PET/CT may be inferior to (18)F-FDOPA PET/CT in the detection PHEOs.
PURPOSE:Pheochromocytomas/paragangliomas (PHEOs/PGLs) overexpress somatostatin receptors and recent studies have already shown excellent results in the localization of these tumors using (68)Ga-labeled somatostatin analogs ((68)Ga-DOTA-SSA), especially in patients with germline succinate dehydrogenase subunit B gene (SDHB) mutations and head and neck PGLs (HNPGLs). The value of (68)Ga-DOTA-SSA has to be established in sporadic cases, including PHEOs. Thus, the aim of this study was to compare (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging in patients with various PHEOs/PGLs with a special emphasis on sporadic cases, including those located in the adrenal gland. DESIGN: (68)Ga-DOTATATE, (18)F-FDOPA PET/CT, and conventional imaging (contrast-enhanced CT and MRI with MR angiography sequences) were prospectively performed in 30 patients (8 with SDHD mutations, 1 with a MAX mutation and 21 sporadic cases) with PHEO/PGL at initial diagnosis or relapse. RESULTS: The patient-based sensitivities were 93 % (28/30), 97 % (29/30), and 93 % (28/30) for (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging, respectively. The lesion-based sensitivities were 93 % (43/46), 89 % (41/46), and 76 % (35/46) for (68)Ga-DOTATATE PET/CT, (18)F-FDOPA PET/CT, and conventional imaging respectively (p = 0.042). (68)Ga-DOTATATE PET/CT detected a higher number of HNPGLs (30/30) than (18)F-FDOPA PET/CT (26/30; p = 0.112) and conventional imaging (24/30; p = 0.024). (68)Ga-DOTATATE PET/CT missed two PHEOs of a few millimeters in size and a large recurrent PHEO. One lesion was considered false-positive on (68)Ga-DOTATATE PET/CT and corresponded to a typical focal lesion of fibrous dysplasia on MRI. Among the 11 lesions missed by conventional imaging, 7 were detected by conventional imaging with knowledge of the PET results (4 HNPGLs, 2 LNs, and 1 recurrent PHEO). CONCLUSION: (68)Ga-DOTATATE PET/CT is the most sensitive tool in the detection of HNPGLs, especially SDHD-related tumors, which may be very small and fail to concentrate sufficient (18)F-FDOPA. The present study further expands the use of (68)Ga-DOTATATE for all patients with HNPGLs, regardless of their genotype. (68)Ga-DOTATATE PET/CT may be inferior to (18)F-FDOPA PET/CT in the detection PHEOs.
Authors: Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Frédéric Castinetti; Alexander Kroiss; Rakesh Kumar; Karel Pacak; David Taieb Journal: Endocr Relat Cancer Date: 2015-06-04 Impact factor: 5.678
Authors: A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2013-01-05 Impact factor: 9.236
Authors: Elise M Blanchet; Corina Millo; Victoria Martucci; Roberto Maass-Moreno; David A Bluemke; Karel Pacak Journal: Clin Nucl Med Date: 2014-03 Impact factor: 7.794
Authors: Helle-Brit Fiebrich; Adrienne H Brouwers; Michiel N Kerstens; Milan E J Pijl; Ido P Kema; Johan R de Jong; Pieter L Jager; Philip H Elsinga; Rudi A J O Dierckx; Jacqueline E van der Wal; Wim J Sluiter; Elisabeth G E de Vries; Thera P Links Journal: J Clin Endocrinol Metab Date: 2009-07-21 Impact factor: 5.958
Authors: Ingo Janssen; Clara C Chen; David Taieb; Nicholas J Patronas; Corina M Millo; Karen T Adams; Joan Nambuba; Peter Herscovitch; Samira M Sadowski; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: J Nucl Med Date: 2015-11-12 Impact factor: 10.057
Authors: Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer Journal: Curr Urol Rep Date: 2021-01-06 Impact factor: 3.092
Authors: Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb Journal: Endocr Relat Cancer Date: 2016-07-12 Impact factor: 5.678
Authors: Vincent Amodru; Pauline Romanet; Ugo Scemama; Marion Montava; Nicolas Fakhry; Frédéric Sebag; Frédéric Castinetti; Jean-Pierre Lavieille; Anderson Loundou; Arthur Varoquaux; Anne Barlier; Karel Pacak; David Taïeb Journal: Head Neck Date: 2018-12-24 Impact factor: 3.147
Authors: Zahraa Abdul Sater; Abhishek Jha; Adel Mandl; Sheila K Mangelen; Jorge A Carrasquillo; Alexander Ling; Melissa K Gonzales; Osorio Lopes Abath Neto; Markku Miettinen; Karen T Adams; Pavel Nockel; Mustapha El Lakis; Karel Pacak Journal: Nucl Med Mol Imaging Date: 2019-02-19